RxDoctor Payments DataLook up a doctor →

Gregory Durm, MD

Hematology & Oncology · Indianapolis, INNPI 1316172299

Payments from drug & device makers

$22,719,051in general payments, 2019–2025

Across 323 payments — averaging $70,338 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$16.1M
  • Amgen$3.2M
  • AstraZeneca$1.2M
  • Eli Lilly$1M
  • Boehringer Ingelheim International GmbH$884K
  • E.r. Squibb & Sons, L.L.C.$111K
  • plus $273K from 10 others
$11,174in research payments, 2019–2025

Across 2 payments — averaging $5587.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$11K

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$22,719,051 in reported general payments places this provider in the 95th percentile of 224 hematology & oncology providers in Indiana.

See all hematology & oncology providers in Indiana

Medicare billing

Part B allowed, 2024
$36,649
Medicare patients
120
Services billed
362

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →